- Can-Fite BioPharma (CANF) jumps 18% in premarket action.
- The company says a Phase 2b study of the A3AR agonist CF101 in RA "met all primary efficacy endpoints."
- ACR20 response rates: CF101, 49%; placebo, 25%; p=0.035.
- Responses were cumulative, indicating "a consistent anti-inflammatory effect."
- The company calls the treatment's safety profile "excellent." (PR)
at Benzinga.com (Jan 6, 2015)